Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclosporine immunosuppression.

D M Canafax, N L Ascher

    Clinical Pharmacy
    |November 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Cyclosporine, a novel immunosuppressant, improves organ transplant survival by blocking T-lymphocyte function. While effective, it requires careful dosing due to potential adverse effects like nephrotoxicity.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Global Transplantation COVID Report March 2020.

    Transplantation·2020
    Same author

    Criminal Organ Retrieval: Unconscionable.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
    Same author

    Development of the Organ Donation and Transplantation Knowledge Survey for use in Asian American adolescents.

    Transplantation proceedings·2010
    Same author

    Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS.

    Neurology·2009
    Same author

    HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2007
    Same author

    Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2007

    Area of Science:

    • Immunology
    • Pharmacology
    • Transplantation Medicine

    Background:

    • Cyclosporine is a new immunosuppressive cyclic undecapeptide.
    • It exhibits slow, variable gastrointestinal absorption and is primarily eliminated by hepatic metabolism.
    • Its mechanism involves blocking T-lymphocyte function without causing myelosuppression.

    Purpose of the Study:

    • To review the chemistry, pharmacokinetics, mechanism of action, clinical efficacy, adverse effects, and administration of cyclosporine.
    • To provide guidance on patient counseling for cyclosporine therapy.

    Main Methods:

    • Review of existing literature and clinical trials comparing cyclosporine with standard immunosuppressive regimens.
    • Analysis of randomized prospective trials in kidney and liver transplantations.

    Related Experiment Videos

  • Evaluation of studies in hepatic and cardiac transplant recipients.

    • Main Results:

    • European Multicenter Trial: 73% graft survival with cyclosporine vs. 53% with azathioprine/steroids at 11 months.
    • Canadian Multicenter Trial: Cyclosporine/prednisone superior to azathioprine/prednisone (83.5% vs. 67% graft survival at 9 months).
    • Improved results observed with cyclosporine and low-dose steroids in hepatic and cardiac transplants.

    Conclusions:

    • Cyclosporine demonstrates significant efficacy in improving organ transplant graft survival.
    • Adverse effects include nephrotoxicity, hepatotoxicity, and electrolyte imbalances.
    • Individualized dosing is crucial, and indications are still being defined for broader use in transplantation.